MDT

97.56

-1.22%↓

A

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

A

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

A

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

A

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

A

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

Search

Revvity Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

104.59 2.83

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

100.64

Max

104.69

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-8.6M

47M

Pardavimai

-21M

699M

P/E

Sektoriaus vid.

52.608

87.826

Pelnas, tenkantis vienai akcijai

0.4

Dividendų pajamingumas

0.29

Pelno marža

6.675

Darbuotojai

11,000

EBITDA

-14M

181M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+11.47% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

0.29%

2.26%

Kitas uždarbis

2026-01-30

Kitas dividendų mokėjimo data

2026-02-06

Kita Ex Dividend data

2026-01-16

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

569M

12B

Ankstesnė atidarymo kaina

101.76

Ankstesnė uždarymo kaina

104.59

Naujienos nuotaikos

By Acuity

16%

84%

30 / 370 reitingas Healthcare

Revvity Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-01-09 22:18; UTC

Rinkos pokalbiai

Changes Needed for Exxon Mobil to Return to Venezuela -- Market Talk

2026-01-09 21:50; UTC

Rinkos pokalbiai

Energy & Utilities Roundup: Market Talk

2026-01-09 21:50; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Basic Materials Roundup: Market Talk

2026-01-09 21:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-01-09 21:50; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2026-01-09 21:43; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

These Stocks Moved the Most Today: Oklo, Vistra, Opendoor, Intel, GM, Revolution Medicines, Tilray, and More -- Barrons.com

2026-01-09 20:39; UTC

Rinkos pokalbiai

GE Vernova Seen With Rising Concern of Overcapacity -- Market Talk

2026-01-09 20:38; UTC

Rinkos pokalbiai

U.S. Natural Gas Falls on Loose Supply Outlook -- Market Talk

2026-01-09 20:36; UTC

Įsigijimai, susijungimai, perėmimai

Cathie Wood's ARK Invest Takes a New Stake in Broadcom -- and Sold Another Hot Stock -- Barrons.com

2026-01-09 20:30; UTC

Rinkos pokalbiai

Oil Makes Weekly Gains in Geopolitically Driven Trade -- Market Talk

2026-01-09 20:15; UTC

Rinkos pokalbiai

Chevron Seen With Modest Opportunity to Boost Venezuela Oil Production -- Market Talk

2026-01-09 20:07; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-01-09 20:07; UTC

Rinkos pokalbiai

Goldman Sachs' Pivot from Consumer Lending Seen as Positive -- Market Talk

2026-01-09 19:58; UTC

Įsigijimai, susijungimai, perėmimai

Merck in Talks to Buy Revolution Medicines for Around $30 Billion -- WSJ

2026-01-09 19:42; UTC

Rinkos pokalbiai

Adobe Seen With Weak Competitive Position Compared to Rivals -- Market Talk

2026-01-09 19:38; UTC

Įsigijimai, susijungimai, perėmimai

Wolters Kluwer Acquires StandardFusion >WTKWY

2026-01-09 19:31; UTC

Uždarbis

Qualcomm Stock Falls After Downgrade. The Apple Supplier Has an iPhone Problem. -- Barrons.com

2026-01-09 19:28; UTC

Uždarbis

Apple Stock Set to Break Brutal Losing Streak. Why It Remains Evercore's 'Top Pick.' -- Barrons.com

2026-01-09 18:30; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Falls by 3 to 409 -- Market Talk

2026-01-09 18:23; UTC

Rinkos pokalbiai

Reports of Canada Oil Sector's Demise Are Premature -- Market Talk

2026-01-09 17:20; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Basic Materials Roundup: Market Talk

2026-01-09 17:20; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-01-09 17:19; UTC

Rinkos pokalbiai

Energy Prices Not Seen Supporting More Drilling -- Market Talk

2026-01-09 17:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2026-01-09 17:07; UTC

Rinkos pokalbiai

McDonald's Promotions Appear Successful -- Market Talk

2026-01-09 17:06; UTC

Rinkos pokalbiai

Oil Futures on Track for Weekly Gains -- Market Talk

2026-01-09 17:05; UTC

Uždarbis

Stocks Sail Past Jobs Data, Tariff Opinion Delay. Earnings Season Looms. -- Barrons.com

2026-01-09 16:57; UTC

Rinkos pokalbiai

Energy Activity Tumbles in 4Q, KC Fed Survey Finds -- Market Talk

2026-01-09 16:46; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-01-09 16:46; UTC

Rinkos pokalbiai

Dollar Could Stay Steady For Now, More Likely to Fall Than Rise -- Market Talk

Akcijų palyginimas

Kainos pokytis

Revvity Inc Prognozė

Kainos tikslas

By TipRanks

11.47% į viršų

12 mėnesių prognozė

Vidutinis 113.38 USD  11.47%

Aukščiausias 123 USD

Žemiausias 105 USD

Remiantis 10 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Revvity Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

10 ratings

6

Pirkti

4

Laikyti

0

Parduoti

Rinkos nuotaikos

By Acuity

30 / 370 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Labai stiprus bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Revvity Inc

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
help-icon Live chat